Curium is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.
Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 800 clients along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, bioanalysis, pharmaco-imaging & artificial intelligence, Oncodesign orients, drives & executes the development of drug candidates from hit findings up to early clinical phases. Oncodesign has specialties in imaging and targeted radiotherapies.
Our expertise & capacities enable to provide imaging solutions to monitor your drug in order to better predict its efficacy. Our multimodal imaging platforms are an open door for non-invasive techniques to understand the pharmacology of your compound in less than 6 months. Finally, we have a unique offering dedicated to pre-clinical evaluation of TRT: a unique combination of our skills in radiochemistry and in vivo pharmaco-imaging in order to assess systemic radiotherapy efficacy.
Oncodesign, a biopharmaceutical company expert in the preclinical development of precision medicine, and ABX-CRO, an independent international CRO with a unique translational medicine approach in radiopharmaceuticals, have joined their know-how from the radiolabeling and appropriate preclinical evaluation via Phase 0 microdosing, through to late stage development. This combined offer ensures end-to-end development of your product from non-clinical to Phase III. Studies in radiolabelled products can be challenging, Oncodesign and ABX-CRO, are working as a translational team to provide optimum research solutions for diagnostic imaging and targeted radiotherapy.
FIELD-LAB is a drug discovery facility that will help you to speed up the development and market launch of new nuclear drugs for cancer treatment. Through supply of small (non) GMP batches of radio chemicals and radio pharmaceuticals, we aim to drive the development of new nuclear drugs.
FIELD-LAB is created for and together with partners, both scientific and industrial. Some of the finest Dutch UMC’s have committed themselves to be part of this initiative. They believe in the beneficial results that will be brought to the Nuclear Medicine society.
Will you partner with us in our quest for the development of new nuclear medicine?
Located near Aix-en-Provence, in France, PMB is a 160-employee SMB. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency…), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.
PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room. Our GMP-compliant R&D iMiLAB synthesizer allows the development of various radiopharmaceuticals using microfluidic cassettes. It can also be used for the production of single doses or small batches.
Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. Nuclear & Precision Health Solutions has 40+ years of expertise and is a national source for both SPECT and PET radiopharmaceuticals, operating the largest network of 130 pharmacies, 30+ cyclotron facilities, and the only Alpha contract manufacturing site in the United States.
Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of immunotherapeutics to pharma and biotech.
Eczacibasi Monrol (EM), Nuclear Products has been leading the Turkish Nuclear Medicine market with the production of high-quality radiopharmaceuticals and R&D activities. EM, has 12 world-class production facilities, 5 in Turkey and 7 worldwide. All facilities are utilized by PET and SPECT products complying fully with all international regulations, including EU GMP, to ensure that its products are of the highest quality. EM, exports 40 countries and is the solution partner supplying start-up, operational services.